B+
Bull case
25%
Probability
Target price
$115.00
+41.0% vs current
DNTH
Dianthus TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$82.00
+0.5% vs current
B-
Bear case
30%
Probability
Target price
$55.00
-32.6% vs current
AI sentiment snapshot
Latest data as of 2026-04-15
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+49.5
Score
AI commentary
The updated primary-source picture is better on execution details than the prior baseline: the March 26, 2026 8-K confirms FDA agreement on trial-screening and safety-language changes, and the March 9, 2026 10-K lays out specific milestones for gMG and MMN [#8-K-2026-03-26] [#10-K-2026-03-09]. Even so, forward visibility is still mostly milestone-based rather than revenue-based, the deterministic score remains negative with only middling evidence quality, and peer support is loose. Netting those factors with the stock trading above the packet’s median analyst target argues for a cautious monitoring stance rather than an aggressive bullish call.
RankAlpha Sentiment Codex - 2026-04-15
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-06-30catalystFDA-backed trial-screening simplification could improve enrollment efficiencyHigh impact
Dianthus disclosed that FDA agreed in March 2026 to remove ANA screening criteria, remove routine ANA testing, and reclassify the hypothetical autoimmune safety risk to drug-induced lupus across ongoing and planned future claseprubart trials; if these changes translate into cleaner screening and lower operational friction, investors could revisit execution odds for the CIDP, gMG, and MMN programs [#8-K-2026-03-26].
2026-07-15eventgMG Phase 3 initiation is the next visible portfolio-expansion checkpointHigh impact
The 10-K states Dianthus reported positive Phase 2 MaGic data in gMG, held an end-of-Phase 2 FDA meeting in 1Q 2026, and expects to initiate a Phase 3 registrational gMG trial in mid-2026. A clean study start would broaden the investment case beyond CIDP, but much of the strategic value likely remains contingent on later execution and data [#10-K-2026-03-09].
2026-09-30catalystInitial Phase 2 MMN top-line data expected in 2H 2026High impact
The 10-K says claseprubart is being evaluated in the Phase 2 MoMeNtum trial for MMN and that initial top-line results are anticipated in the second half of 2026; this is the cleanest forward data milestone in the current primary-source set, but the setup remains binary and pre-commercial [#10-K-2026-03-09].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-15 • Updated nightlySource: Internal modelMethodology